<DOC>
	<DOCNO>NCT01581151</DOCNO>
	<brief_summary>This study seek compare dexamethasone implant rescue intravitreal ranibizumab monthly intravitreal ranibizumab treatment macular edema secondary branch central retinal vein occlusion . This base null hypothesis dexamethasone implant rescue ranibizumab inferior best correct visual acuity six month compare monthly ranibizumab alone .</brief_summary>
	<brief_title>Ozurdex With Rescue Lucentis Treating Macular Edema Secondary Retinal Vein Occlusion</brief_title>
	<detailed_description>Dexamethasone intravitreal implant ( DEX implant ; OZURDEX , Allergan , Inc. , Irvine , CA ) Ranibizumab ( Lucentis , Genentech , Inc. , South San Francisco , CA ) need group : - Patients receive dexamethasone intravitreal implant injection day 0 . Injection procedure identical previously described.8,19,20 Topical tetracaine drop give , lid speculum insert , 5 % povidone iodine drop give . After subconjunctival injection 2 % lidocaine , 0.7mg DEX implant insert par plana use customize , single use , 22-gauge applicator . Patients treat topical ophthalmic antibiotic four time daily three day procedure . - During monthly visit 1,2,3 , 5 , patient receive ranibizumab intravitreal injection macula SD-OCT visit show mean central foveal thickness ≥ 250 μm best-corrected visual acuity 20/40 worse . The injection procedure describe next section . - During monthly visit 4 , patient receive dexamethasone intravitreal implant injection macula SD-OCT visit show mean central foveal thickness ≥ 250 μm best-corrected visual acuity 20/40 worse . Monthly Ranibizumab ( Lucentis , Genentech , Inc. , South San Francisco , CA ) group : - Patients receive ranibizumab intravitreal injection day 0 . During visit , patient receive ranibizumab intravitreal injection . The protocol use term `` monthly '' represent 30 day interval treatment . The minimal interval treatment may 25 day . - Injection procedure identical previously described.8,19,20 Topical tetracaine drop give , lid speculum insert , 5 % povidone iodine drop give . After subconjunctival injection 2 % lidocaine , 30-gauge needle inserted par plana , 0.5 mg ( 0.05mL ) drug inject .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Signed informed consent form 18 90 yearold men woman Women must postmenopausal least 12 month study enrollment , surgically sterile . Potential child bear woman must negative serum pregnancy test within 14 day prior first treatment practice effective contraception least 120 day follow last dose injection . Patient Wills Eye Institute Retina service , include MidAtlantic Retina office . Healthy enough participate study . Willing able consent participation study . Retinal vein occlusion : Must diagnose within two week onset symptom Best Corrected Visual Acuity ( BCVA ) initial presentation 20/40 20/320 No contraindication intravitreal injection dexamethasone implant ranibizumab Central foveal thickness great 250 Spectral DomainOCT Unknown duration symptom prior diagnosis . Patients history prior intravitreal dexamethasone antiVEGF grid laser . Patients diabetic retinopathy . Patients agerelated macular degeneration . Patients optic neuropathy . Patients retinal detachment history retinal detachment . Patients significant epiretinal membrane . Patients history choroidal neovascularization . Patients glaucoma visual field loss document Humphrey Visual Field test ocular hypertension require 2 medication control IOP study eye . Patients clinically significant medium opacity . Patients use anticipate use systemic steroid . Patients uncontrolled systemic disease . Patients aphakia anteriorchamber intraocular lens . Patients active neovascularization iris , disc , retina .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>retinal vein occlusion</keyword>
	<keyword>ozurdex</keyword>
	<keyword>lucentis</keyword>
	<keyword>BCVA</keyword>
	<keyword>foveal thickness</keyword>
</DOC>